Target Name: CCNF
NCBI ID: G899
Review Report on CCNF Target / Biomarker Content of Review Report on CCNF Target / Biomarker
CCNF
Other Name(s): FTDALS5 | Cyclin-F (isoform 1) | CCNF_HUMAN | F-box only protein 1 | FBX1 | cyclin F | G2/mitotic-specific cyclin-F | CCNF variant 1 | FBXO1 | Cyclin F, transcript variant 1 | Cyclin-F

The Potential of CCNF as A Drug Target for FXS and Other Neurological Conditions

The field of neurodegenerative diseases has seen significant progress in recent years, with new treatments and therapies being developed for conditions such as Alzheimer's disease, Parkinson's disease, and Huntington's disease. However, there are still many devastating diseases that have no known treatment, and research is ongoing to find new ways to treat them. One of these diseases is Fragile X Syndrome (FXS), a genetic disorder that affects around 1 in 40 people. The condition is characterized by a range of symptoms, including cognitive decline, repetitive behaviors, and social interaction difficulties. While there are currently no approved treatments for FXS, research is ongoing to find new drug targets or biomarkers. One such potential drug target is the protein known as CCNF (C-cysteinyl-cysteine 鈥嬧?媙itrogen-containing), which is a protein that is expressed in the brain and has been linked to a number of neurological conditions. In this article, we will explore the potential of CCNF as a drug target for FXS and other neurological conditions.

The ProteinCCNF and Its Functions

CCNF stands for cysteine-cysteine 鈥嬧?媙itrogen-containing, and it is a type of protein that is expressed in the brain and other tissues. The protein is made up of four amino acids, which are nitrogen-containing cysteine 鈥嬧?媟esidues. These cysteine 鈥嬧?媟esidues are important for the structure and function of the protein, and they play a key role in its regulation of various cellular processes.

One of the key functions of CCNF is its role in the regulation of protein synthesis. In the brain, CCNF is involved in the production and degradation of a number of proteins, including neurotransmitter receptors, ion channels, and other proteins that are important for brain function. It is also involved in the regulation of cellular processes such as cell adhesion, migration, and survival.

In addition to its role in protein synthesis and regulation, CCNF is also involved in the regulation of cellular signaling pathways. It is a negative regulator of several signaling pathways, including the TGF-β pathway. This pathway is involved in the regulation of cell growth , differentiation, and survival, and it is a key factor in the development and progression of many neurological conditions.

The Potential of CCNF as a Drug Target

The potential of CCNF as a drug target for FXS and other neurological conditions is being investigated as a result of recent studies. FXS is a genetic disorder that is characterized by a range of symptoms, including cognitive decline, repetitive behaviors, and social interaction difficulties. There are currently no approved treatments for FXS, and researchers are looking for new drug targets or biomarkers that can be used to treat the condition.

One potential drug target that is being investigated is CCNF. Research has shown that CCNF is expressed in the brains of individuals with FXS, and that it is involved in the regulation of various cellular processes that are important for brain function. In addition, studies have shown that CCNF is involved in the regulation of several signaling pathways, including the TGF-β pathway. This pathway is involved in the regulation of cell growth, differentiation, and survival, and it is a key factor in the development and progression of many neurological conditions.

One potential way to target CCNF is through the use of small molecules, which can be used to inhibit its activity. Researchers have shown that small molecules can be used to inhibit the activity of CCNF and prevent it from regulating the production and degradation of other proteins. This suggests that CCNF may be an attractive target for drugs that are being developed to treat FXS and other neurological conditions.

Conclusion

In conclusion, CCNF is a protein that is expressed in the brain and has been linked to a number of neurological conditions. The potential of CCNF as a drug target for FXS and other conditions is being investigated

Protein Name: Cyclin F

Functions: Substrate recognition component of a SCF (SKP1-CUL1-F-box protein) E3 ubiquitin-protein ligase complex which mediates the ubiquitination and subsequent proteasomal degradation of target proteins (PubMed:20596027, PubMed:22632967, PubMed:27653696, PubMed:26818844, PubMed:27080313, PubMed:28852778). The SCF(CCNF) E3 ubiquitin-protein ligase complex is an integral component of the ubiquitin proteasome system (UPS) and links proteasome degradation to the cell cycle (PubMed:8706131, PubMed:20596027, PubMed:27653696, PubMed:26818844). Mediates the substrate recognition and the proteasomal degradation of various target proteins involved in the regulation of cell cycle progression and in the maintenance of genome stability (PubMed:20596027, PubMed:22632967, PubMed:27653696, PubMed:26818844). Mediates the ubiquitination and proteasomal degradation of CP110 during G2 phase, thereby acting as an inhibitor of centrosome reduplication (PubMed:20596027). In G2, mediates the ubiquitination and subsequent degradation of ribonucleotide reductase RRM2, thereby maintaining a balanced pool of dNTPs and genome integrity (PubMed:22632967). In G2, mediates the ubiquitination and proteasomal degradation of CDC6, thereby suppressing DNA re-replication and preventing genome instability (PubMed:26818844). Involved in the ubiquitination and degradation of the substrate adapter CDH1 of the anaphase-promoting complex (APC/C), thereby acting as an antagonist of APC/C in regulating G1 progression and S phase entry (PubMed:27653696). May play a role in the G2 cell cycle checkpoint control after DNA damage, possibly by promoting the ubiquitination of MYBL2/BMYB (PubMed:25557911)

The "CCNF Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CCNF comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

CCNG1 | CCNG2 | CCNH | CCNI | CCNI2 | CCNJ | CCNJL | CCNK | CCNL1 | CCNL2 | CCNO | CCNP | CCNQ | CCNQP1 | CCNT1 | CCNT2 | CCNT2-AS1 | CCNT2P1 | CCNY | CCNYL1 | CCNYL2 | CCP110 | CCPG1 | CCR1 | CCR10 | CCR12P | CCR2 | CCR3 | CCR4 | CCR4-NOT transcription complex | CCR5 | CCR5AS | CCR6 | CCR7 | CCR8 | CCR9 | CCRL2 | CCS | CCSAP | CCSER1 | CCSER2 | CCT2 | CCT3 | CCT4 | CCT5 | CCT6A | CCT6B | CCT6P1 | CCT6P3 | CCT7 | CCT8 | CCT8L1P | CCT8L2 | CCT8P1 | CCZ1 | CCZ1B | CCZ1P-OR7E38P | CD101 | CD101-AS1 | CD109 | CD14 | CD151 | CD160 | CD163 | CD163L1 | CD164 | CD164L2 | CD177 | CD177P1 | CD180 | CD19 | CD1A | CD1B | CD1C | CD1D | CD1E | CD2 | CD200 | CD200R1 | CD200R1L | CD207 | CD209 | CD22 | CD226 | CD24 | CD244 | CD247 | CD248 | CD24P2 | CD27 | CD27-AS1 | CD274 | CD276 | CD28 | CD2AP | CD2BP2 | CD3 Complex (T Cell Receptor Complex) | CD300A | CD300C | CD300E